<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">50036</article-id><article-id pub-id-type="doi">10.7554/eLife.50036</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-46085"><name><surname>Palmer</surname><given-names>Adam C</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5028-7028</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-150795"><name><surname>Chidley</surname><given-names>Christopher</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8212-3148</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-6654"><name><surname>Sorger</surname><given-names>Peter K</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3364-1838</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Laboratory of Systems Pharmacology</institution>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1025"><name><surname>Sawyers</surname><given-names>Charles L</given-names></name><role>Reviewing editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>peter_sorger@hms.harvard.edu</email> (PS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>11</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e50036</elocation-id><history><date date-type="received"><day>09</day><month>07</month><year>2019</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Palmer et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Palmer et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-50036-v1.pdf"/><abstract><p>Curative cancer therapies are uncommon and nearly always involve multi-drug combinations developed by experimentation in humans; unfortunately, the mechanistic basis for the success of such combinations has rarely been investigated in detail, obscuring lessons learned. Here we use isobologram analysis to score pharmacological interaction, and clone tracing and CRISPR screening to measure cross-resistance among the five drugs comprising R‑CHOP, a combination therapy that frequently cures Diffuse Large B-Cell Lymphomas. We find that drugs in R‑CHOP exhibit very low cross-resistance but not synergistic interaction: together they achieve a greater fractional kill according to the null hypothesis for both the Loewe dose-additivity model and the Bliss effect-independence model. These data provide direct evidence for the 50-year old hypothesis that a curative cancer therapy can be constructed on the basis of independently effective drugs having non-overlapping mechanisms of resistance, without synergistic interaction, which has immediate significance for the design of new drug combinations.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P50-GM107618</award-id><principal-award-recipient><name><surname>Palmer</surname><given-names>Adam C</given-names></name><name><surname>Chidley</surname><given-names>Christopher</given-names></name><name><surname>Sorger</surname><given-names>Peter K</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U54-CA225088</award-id><principal-award-recipient><name><surname>Palmer</surname><given-names>Adam C</given-names></name><name><surname>Chidley</surname><given-names>Christopher</given-names></name><name><surname>Sorger</surname><given-names>Peter K</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1072965</award-id><principal-award-recipient><name><surname>Palmer</surname><given-names>Adam C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Peter K Sorger, is a member of the SAB or Board of Directors of Merrimack Pharmaceuticals, Glencoe Software,Applied Biomath and RareCyte Inc and has equity in these companies. In the last five years the Sorgerlab has received research funding from Novartis and Merck. P.K.S. declares that none of theserelationships are directly or indirectly related to the content of this manuscript.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated during this study are included in the manuscript and supporting files. Source data is provided for all clone tracing and CRISPR screen experiments.</p></sec><supplementary-material><ext-link xlink:href="elife-50036-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>